Monoclonal antibodies market (original) (raw)

Nature Reviews Drug Discovery volume 3, pages 383–384 (2004)Cite this article

Following the success of recombinant proteins, therapeutic monoclonal antibodies (mAbs) represent the second wave of innovation created by the biotechnology industry during the past twenty years. Between 2001 and 2002, the value of the global therapeutic mAb market grew by 37% to US 5.4billion.ChimericmAbsweretheundisputedleaders,with435.4 billion. Chimeric mAbs were the undisputed leaders, with 43% growth and US 5.4billion.ChimericmAbsweretheundisputedleaders,with433.8 billion in sales, followed by humanized mAbs with more than US 1.4billioninsalesandgrowthof291.4 billion in sales and growth of 29%. The current global clinical antibody pipeline, which comprises 132 products in development and is dominated by humanized (42%) and fully human (28%) mAbs, is poised to deliver as many as 16 new products between 2004 and 2008. As a result of growth in existing markets for mAb therapeutics, and the opening of new ones, the global market is projected to increase to US 1.4billioninsalesandgrowthof2916.7 billion in 2008.

mAbs approved for marketing

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

Author information

Authors and Affiliations

  1. Senior Research Fellow at Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, 02111, Massachusetts, USA
    Janice Reichert Ph.D.
  2. Heads Biotechnology Analysis at Datamonitor Healthcare, 108–110 Finchley Road, Charles House, London, NW3 5JJ, UK
    Alex Pavlou Ph.D.

Authors

  1. Janice Reichert Ph.D.
    You can also search for this author inPubMed Google Scholar
  2. Alex Pavlou Ph.D.
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Reichert, J., Pavlou, A. Monoclonal antibodies market.Nat Rev Drug Discov 3, 383–384 (2004). https://doi.org/10.1038/nrd1386

Download citation

This article is cited by